Brentuximab [BRE7]
Re-use of brentuximab in relapsed/refractory Hodgkin lymphoma ADULT patients:
- An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
- The patient has relapsed or refractory CD30+ Hodgkin lymphoma.
- The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant
- Previous use of brentuximab achieved a partial/complete response to brentuximab
- Brentuximab is being used as a bridge to allogeneic stem cell transplantation or donor lymphocyte infusion
- Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response in
- The patient is an adult* *note there is a separate blueteq form to be used for brentuximab in this indication in children
- No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve). *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process
- A maximum of 16 cycles of brentuximab will be administered to the patient when combining this reuse and previous cycles of brentuximab
- Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).
NHS funded From: 26 September 2017
Additional information
Form version:
CDF Managed Access: NA
NICE Technology Appraisal: TA524 (formerly TA446) (13 June 2018)
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.